The outlook of companies tied to Sildenafil's legacy presents a challenging investment landscape. While the initial boom generated substantial returns , generic competition have significantly eroded sales . Investing in associated pharmaceutical companies now requires a thorough assessment of intellectual property protection , evolving healthcare s